A Case of Resistant Hypocalcemia Treated with Teriparatide

Year 2021, Volume: 3 Issue: Supplement 1, 92 - 93, 07.03.2021

Ensar Aydemir , Canan Ersoy , Özen Öz Gül , Soner Cander , Yasemin Aydoğan Ünsal , Coşkun Ateş , Erdinç Ertürk

https://doi.org/10.46310/tjim.882244

Abstract

Postsurgical chronic hypoparathyroidism is most commonly seen in adults. Synthetic recombinant human parathyroid hormone (rhPTH) 1-34 can be used to stabilize serum calcium levels in patients with resistant hypocalcemia in rare conditions.
Here we report a 52-year-old woman with postsurgical uncontrolled hypocalcemia despite the usual therapy. Once-daily treatment with PTH 1-34 maintained serum calcium within the normal range and reduced the dose of previous medical therapies.

Keywords

Hypoparathyroidism, Hypocalcemia, Teriparatide

References

• Reference1. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26(10):2317-2337. doi:10.1002/jbmr.483
• Reference2. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359(4):391-403. doi:10.1056/NEJMcp0803050
• Reference3. Russell CF, Edis AJ. Surgery for primary hyperparathyroidism: experience with 500 consecutive cases and evaluation of the role of surgery in the asymptomatic patient. Br J Surg. 1982;69(5):244-247. doi:10.1002/bjs.1800690503
• Reference4. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996;276(8):631-636.
• Reference5. Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med. 2019;380(18):1738-1747. doi:10.1056/NEJMcp1800213
• Reference6. Gafni RI, Langman CB, Guthrie LC, et al. Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity. J Bone Miner Res. 2018;33(10):1741-1747. doi:10.1002/jbmr.3480
• Reference7. Goujard C, Salenave S, Briot K, Chanson P, Grimon G, Kamenický P. Treating hypoparathyroidism with recombinant human parathyroid hormone (1-34): long-term safety concerns. Lancet. 2020;395(10232):1304. doi:10.1016/S0140-6736(20)30538-9